Search
Menu
Home
HTB
2024
July
July 2024
Contents
Editorial
i-Base printed resources: please order now while stocks last
Conference reports
AIDS 2024: Lenacapavir as PrEP is “beyond wonderful” but PURPOSE 1 study tells us so much more
Lenacapavir could be produced for $40 a year: 1000-fold lower than current US price for treating MDR HIV
AIDS 2024: Introduction to AIDS 2024
UNAIDS report: The urgency of now – AIDS at a crossroads.
New community call to challenge social settings that drive HIV-related stigma
HIV research to watch out for at the AIDS 2024 conference
Antiretrovirals
HIV pipeline: global overview for people in LMICs
Treatment access
CHAI six-monthly market report (July 2024)
Guidelines
South African guidelines do not include dapivirine ring: low efficacy and high price
Updated WHO guidelines for HIV PEP (July 2024)
New US screening guidelines to reduce risk of anal cancer in people living with HIV
Side effects
Semaglutide in people with HIV: reduces both central and peripheral fat worsening lipoatrophy
HTB RSS
Early access
Semaglutide reduces alcohol and cigarette use in a randomised phase 2 study
12 February 2025
IAS public letter: Why HIV could be poised for a monumental comeback
6 February 2025
Lenacapavir for PrEP submitted to EMA for EU and global use
4 February 2025
New mpox vaccination sites open in the UK
3 February 2025
All early access reports
Current issues
February 2025
January 2025
December 2024
Back issues
Special report
Impact of US elections and executive orders on global health: waiver covers PEPFAR with restrictions
1 February 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate